Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Corticosteroids sparing effect of artemisia annua sublingual immunotherapy: A prospective study in pediatric seasonal allergic rhinoconjunctivitis (INCs sparing and efficacy of Artemisia annua SLIT in pediatric SARC).
Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the efficacy and safety of Artemisia annua sublingual immunotherapy (SLIT) in pediatric patients with seasonal allergic rhinoconjunctivitis (SARC), and its specific impact on assessing the reduction in intranasal corticosteroids (INCs) use for individual patients.
methodsSixty pediatric patients (aged 3–17 years) with SARC were recruited at the Department of Otolaryngology of the First Affiliated Hospital of Xi’an Jiaotong University from February to August 2023. Participants were randomly allocated to either the SLIT group (n = 30) or the control group (n = 30). The SLIT group received Artemisia annua-SLIT with symptomatic medication while the control group received symptomatic medication only. The study continued until October 2024. Four nasal symptom scores, two eye symptom scores, and medication usage of the patients during 2022 (baseline), 2023 and 2024 pollen seasons were recorded, as well as adverse events (AEs) during the study.
resultsEighteen patients in the SLIT group and 22 in the control group completed the study. Compared to the control group, the SLIT group demonstrated significantly lower scores for the total rhinoconjunctivitis symptom score (TRSS), total medication score (TMS), visual analogue scale (VAS), and the combined symptom and medication score (CSMRS) throughout both the 2023 and 2024 pollen seasons. Furthermore, when compared to the baseline, the SLIT group showed significant reductions in the TRSS, TMS, VAS, and CSMRS following treatment. Notably, 88.89% of patients in the SLIT group discontinued INCs use by the end of the study, and 83.33% achieved substantial clinical improvement, defined as a > 50% reduction in CSMRS. No serious AEs were observed in the SLIT group throughout the treatment period.
conclusionsArtemisia annua-SLIT administered during two consecutive pollen seasons demonstrated clinical efficacy and safety in pediatric patients with SARC and significantly reduced their dependence on INCs.
Indexed as
Identifiers
41838156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.